 |
human recombinant dual-variable domain immunoglobulin G1 monoclonal antibody that selectively neutralizes tumor necrosis factor-alpha and interkeukin-17A |
|---|---|
| Trade Name | |
| Orphan Indication | Pediatric patients 0 to <18 yrs of age with oligoarticular-course and polyarticular-course juvenile idiopathic arthritis |
| USA Market Approval | USA |
| USA Designation Date | 2016-02-04 00:00:00 |
| Sponsor | AbbVie, Inc.;1 North Waukegan Road;North Chicago, Illinois, 60064 |
